Information Provided By: 
Fly News Breaks for May 29, 2018
CGIX
May 29, 2018 | 07:12 EDT
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Cancer Genetics to $3 saying the company's growth has persistently lagged his projections. Nevertheless, Cancer Genetics is gradually growing sales, and its net loss should drop substantially starting late this year, Selvaraju tells investors in a research note. He reiterates a Buy rating on the shares.
News For CGIX From the Last 2 Days
There are no results for your query CGIX
